![Internal structure of a powder inhaler revealed using CT scan [Adapted from Scan of the Month].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Inhaler-feature-300x278.png)
![Internal structure of a powder inhaler revealed using CT scan [Adapted from Scan of the Month].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Inhaler-feature.png)
Take a look inside drug delivery devices
Explore the internal workings of two of the most common drug delivery devices - the powder asthma inhaler and the EpiPen®.
List view / Grid view
News
$6mn grant to advance purification membranes for viral vectors
With the grant, researchers will create a scalable, downstream purification platform that will replace the standard processes, accelerating viral vector production for vaccines.
Common pharma compliance concerns cited by FDA warning letters
A review of the last decade of FDA warning letters finds quality control operations, manufacturing process validation, and data record and integrity are the key points of scrutiny.
Trends in biopharma contract manufacturing 2022
As biopharmaceuticals become an increasingly important part of the drug development pipeline and market, EPR discusses key trends in the outsourcing of their manufacturing.
UNICEF signs first ever malaria vaccine supply contract with GSK
Securing 18 million doses of GSK’s RTS,S malaria vaccine, UNICEF calls the contract a major breakthrough for child health.
Pharma contract manufacturing market to grow to $130bn by 2026
Growth in the global pharmaceutical contract manufacturing market will be driven by rising consumption of medicines and increasing commercialisation of generic and innovative therapies, among other factors.
FDA approves Zynteglo gene therapy for beta-thalassemia patients
bluebird bio’s Zynteglo (betibeglogene autotemcel), a one-time treatment for transfusion-dependent beta-thalassemia, will roll out with a $2.8mn price tag per dose.
Merck to support development of Orna’s circular RNA (oRNA) therapies
Under a collaboration agreement Merck will pay Orna $150 million to support the progress of multiple oRNA vaccine and therapeutic programmes.
Formulation development outsourcing market to be worth over $60bn by 2030
Market research suggests the global formulation development outsourcing market will significantly expand in coming years, owing to disease burden and R&D expenditure.
![Governor John Carney, Lieutenant Governor Bethany Hall-Long, Mayor Kenneth Branner Jr, Delaware Prosperity Partnership President Kurt Foreman, WuXi AppTec Chairman and CEO Dr Ge Li, WuXi AppTec Co-CEO and WuXi STA CEO Dr Minzhang Chen, and others celebrating the groundbreaking for the WuXi STA Middletown campus [Credit: WuXi STA].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-STA-groundbreaking-scaled-e1660730270899-300x278.jpeg)
![Governor John Carney, Lieutenant Governor Bethany Hall-Long, Mayor Kenneth Branner Jr, Delaware Prosperity Partnership President Kurt Foreman, WuXi AppTec Chairman and CEO Dr Ge Li, WuXi AppTec Co-CEO and WuXi STA CEO Dr Minzhang Chen, and others celebrating the groundbreaking for the WuXi STA Middletown campus [Credit: WuXi STA].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/WuXi-STA-groundbreaking-scaled-e1660730270899.jpeg)
WuXi STA breaks ground on new Delaware manufacturing facility
The new 190-acre pharmaceutical manufacturing campus will provide formulation development, clinical and commercial drug product manufacturing services.
MHRA approves Pluvicto® and Locametz® for prostate cancer
The UK’s regulator approved Novartis’ radioligand therapy Pluvicto®▼ and radioactive diagnostic agent Locametz® for use in advanced prostate cancer.
Queen’s Award for Enterprise goes to SGS’s Quay Pharma
SGS’s CDMO Quay Pharma awarded UK’s highest accolade for business success in overseas sales, Queen's Award for Enterprise: International Trade.
UK approves Moderna’s bivalent COVID-19 vaccine
MHRA approves Moderna’s adapted COVID-19 vaccine, Spikevax bivalent Original/Omicron, for use as a booster.
Phase III trial shows tislelizumab improves outcomes for liver cancer patients
Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.
4mn dose shortage of GSK’s childhood rotavirus vaccine expected
With vaccination programmes fighting to recover after the pandemic fuelled the “largest backslide” in three decades, GSK says manufacturing challenges will leave a shortage of rotavirus vaccines.
